- Home
- REAL vs ORKA Comparison
REAL vs ORKA Comparison
Compare REAL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- ORKA
- Stock Information
- Founded
- REAL 2011
- ORKA 2004
- Country
- REAL United States
- ORKA United States
- Employees
- REAL N/A
- ORKA N/A
- Industry
- REAL Other Specialty Stores
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- REAL Consumer Discretionary
- ORKA Health Care
- Exchange
- REAL Nasdaq
- ORKA Nasdaq
- Market Cap
- REAL 1.2B
- ORKA 1.2B
- IPO Year
- REAL 2019
- ORKA N/A
- Fundamental
- Price
- REAL $10.26
- ORKA $27.45
- Analyst Decision
- REAL Strong Buy
- ORKA Strong Buy
- Analyst Count
- REAL 5
- ORKA 7
- Target Price
- REAL $12.20
- ORKA $42.86
- AVG Volume (30 Days)
- REAL 3.1M
- ORKA 569.7K
- Earning Date
- REAL 11-10-2025
- ORKA 11-12-2025
- Dividend Yield
- REAL N/A
- ORKA N/A
- EPS Growth
- REAL N/A
- ORKA N/A
- EPS
- REAL N/A
- ORKA N/A
- Revenue
- REAL $636,971,000.00
- ORKA N/A
- Revenue This Year
- REAL $14.27
- ORKA N/A
- Revenue Next Year
- REAL $9.94
- ORKA N/A
- P/E Ratio
- REAL N/A
- ORKA N/A
- Revenue Growth
- REAL 12.68
- ORKA N/A
- 52 Week Low
- REAL $2.71
- ORKA $5.49
- 52 Week High
- REAL $11.79
- ORKA $31.13
- Technical
- Relative Strength Index (RSI)
- REAL 53.65
- ORKA 75.23
- Support Level
- REAL $9.53
- ORKA $24.46
- Resistance Level
- REAL $10.99
- ORKA $29.20
- Average True Range (ATR)
- REAL 0.60
- ORKA 2.01
- MACD
- REAL -0.13
- ORKA 0.67
- Stochastic Oscillator
- REAL 31.93
- ORKA 84.29
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.